Premium
P3‐288: A randomized, double‐blind, placebo‐controlled, multiple ascending dose study of hdac inhibition for modulation of apoj/clusterin expression as a risk factor for Alzheimer's disease
Author(s) -
Jicha Gregory A.,
Abner Erin L.,
Kryscio Richard J.,
Estus Steve
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.1661
Subject(s) - clusterin , placebo , histone deacetylase inhibitor , medicine , pharmacology , biology , histone deacetylase , oncology , endocrinology , gastroenterology , apoptosis , pathology , gene , histone , genetics , alternative medicine